Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site.-临床诊疗知识库

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site.

| 浏览：94

作者：

Elyse E, Lower；Shagufta, Khan；Diane, Kennedy；Robert P, Baughman

来源：

Breast cancer (Dove Medical Press) 2017 年 9卷

标签：

HER-2/neu breast cancer estrogen receptor progesterone receptor survival tumor discordance

Hormone receptor and HER-2/neu discordance between the primary lesion and first metastasis has been reported. This study was performed to determine further biomarker discordance rates between the first and subsequent metastatic breast cancer lesions.We performed a retrospective review of paired biomarkers from primary breast cancers compared to first reported and subsequent metastases from 103 patients with breast cancer. The estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu status were reported at all three time points. In addition, hormone, cytotoxic, and targeted treatments were recorded for primary and metastatic disease, and survival was determined.Between the primary and first metastases, discordance rates for ER, PR, and HER-2/neu were 15.8

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求，方便快速、便捷的获取实用的医学信息，辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍

临床诊疗知识库现支持机构用户及个人包时用户开通服务。如需开通机构账号，请机构管理员联系我们，联系电话：010-58882667；个人包时开通请直接点击“个人包时订购”，开通后即可使用。

相似文献